Raptor Slow Release Treatment At Trial Stage

US Pharmaceutical firm, Raptor, have successfully raised funds via a share issue to fund the next stage of trials for their new Cystinosis treatment.

DR Cysteamine is the first drug from Raptor, and it is hoped that its slow release mechanism will allow Cystinotics to take their medication only twice a day, rather than the current four times a day. The new funding will allow Raptor to continue their operations until the end of 2011, by which time they hope to have completed trials and submitted the drug for release within the USA. The trial will involve approximately 30 Cystinotics in the USA and we look forward to hearing the results.

Online News Report

Raptor’s Website

Comments are closed.

QUALIFY-US Study Participants are needed for the testing of a newly developed questionnaire to measure the [...] Read more...
CNE International Conference 2024 Cystinosis Network Europe and Cystinosis Foundation UK are delighted to announce the 2024 [...] Read more...
Cystinosis Comic Book Series by Artist Kevin McCalla The Cystinosis Research Network in the US has teamed up with Kevin McCalla, a young artist who [...] Read more...
Summer 2023 Newsletter The Summer 2023 edition of our email newsletter is available to view at the link below. CFUK [...] Read more...
All website content copyright Cystinosis Foundation UK (Charity No.1074885) 1997-2013, except where explicitly stated.
Data Protection Act Registration Number: Z9880997. Please refer to our terms and conditions and our privacy policy.